BioLife Solutions, Inc. (NASDAQ:BLFS) (“BioLife” or the “Company”), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, announced today an additional delay in the filing of its Annual Report on Form 10-K for the year ended December 31, 2021 (the “Form 10-K”).
Blue Water Vaccines Announces Sponsored Research Agreement Amendment To Continue Funding Universal Influenza Vaccine Development At The University of Oxford
Blue Water Vaccines Inc. ("BWV" or "Blue Water Vaccines" or "the Company") a biopharmaceutical company developing transformational vaccines to address significant global health
